Q 北京时间12月29日清晨，《新英格兰医学杂志》（NEJM）发表一项中国产新冠药物3期随机对照临床试验，其结果表明，对于有高危因素的轻中度新冠成人患者，在至持续临床康复时间方面，国产新冠药物VV116是4天，非劣于辉瑞帕罗韦德（Paxlovid，奈玛特韦-利托那韦）的5天，两者的药物风险比为1.17，且VV116的不良事件更少。 https://www.wenxuecity.com/news/2022/12/29/12049911.html UQ Q VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of ... https://www.nejm.org › doi › full › NEJMoa2208822 20 hours ago — Conclusions. Among adults with mild-to-moderate Covid-19 who were at risk for progression, VV116 was noninferior to nirmatrelvir–ritonavir with ... Victoria Yan (@victoriacyanide) / Twitter https://twitter.com › victoriacyanide 10 hours ago — Original Article from The New England Journal of Medicine — VV116 versus ... VV116"an oral remdesivir analogue" was noninferior to Paxlovid w respect to the ... VV116 Versus PAXLOVID Phase III Registrational Trial for ... https://www.mypanhandle.com › globenewswire › vv1... 24 May 2022 — --the study reached its primary endpoint(VV116 was statistically superior) and secondary efficacy endpoint. --VV116 has a favorable safety ... UQ
除非你去住山洞与世隔绝也不看病。中国的医疗资源都在大城市，大城市的医疗资源都在三甲，否则你以为别人都傻了，有病非得去三甲医院排队？
https://www.wenxuecity.com/news/2022/12/29/12049911.html UQ
Q VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of ... https://www.nejm.org › doi › full › NEJMoa2208822 20 hours ago — Conclusions. Among adults with mild-to-moderate Covid-19 who were at risk for progression, VV116 was noninferior to nirmatrelvir–ritonavir with ...
Victoria Yan (@victoriacyanide) / Twitter https://twitter.com › victoriacyanide 10 hours ago — Original Article from The New England Journal of Medicine — VV116 versus ... VV116"an oral remdesivir analogue" was noninferior to Paxlovid w respect to the ...
VV116 Versus PAXLOVID Phase III Registrational Trial for ... https://www.mypanhandle.com › globenewswire › vv1... 24 May 2022 — --the study reached its primary endpoint(VV116 was statistically superior) and secondary efficacy endpoint. --VV116 has a favorable safety ... UQ